- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00483119
Randomized Trial of IVIg With or Without Cyclophosphamide in Pemphigus
Phase 2 Randomized Trial of IVIg With or Without Cyclophosphamide in Pemphigus
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Pemphigus is a serious and life-threatening autoimmune disease characterized by blisters and erosions that occur on the skin and oral mucosa. It is caused by autoantibodies that attack desmoglein 1 and 3, adhesion molecules that are present on the surface of the cells (keratinocytes) that make up the superficial layer of the skin. As a result these cells stop sticking together, and come apart resulting in the formation of blisters on the skin.
Pemphigus is usually treated with systemic corticosteroids often given together with immunosuppressive drugs such as Cytoxan (cyclophosphamide), Imuran (azathioprine), methotrexate, CellCept (mycophenolate mofetil) and others. However, the prolonged and high doses of systemic steroids and other immunosuppressive agents used to treat the disease are associated with significant toxicity.
A new treatment which is now being used to treat pemphigus patients that are unresponsive, or that have developed complications to conventional treatment is IVIg (intravenous immunoglobulin). IVIg consists of one of the protein fractions present in blood. It is the fraction that contains antibodies and is called immunoglobulin (Ig). It is purified from blood that has been collected from thousands of donors and treated to remove potential infectious agents. It is administered intravenously (IV) over several hours, several days in succession. The cycles are usually repeated every 2 to 4 weeks until the disease is controlled.
IVIg treatment is currently given in either of two ways, either by itself or with an immunosuppressive drug such as cyclophosphamide or azathioprine. It is unknown which of these two procedures is better. This trial is being conducted to determine which treatment is more effective.
The trial is being conducted in patients with pemphigus that are not responding to, or have developed complications from, standard treatment. All patients will be treated with IVIg administered using a standard protocol. The IVIg will be given daily for 4 days, and this cycle will be repeated every other week for a total of 4 cycles. In addition, half of the patients will be selected by chance to also be treated with cyclophosphamide, an immunosuppressive drug often used to treat other autoimmune diseases including pemphigus. The cyclophosphamide is a pill that is taken 3 times a day. A total of 12 patients will be treated in each arm of the trial. The trial is being conducted by Dr. Jean-Claude Bystryn at the New York University Medical Center.
The extent and activity of the disease, as well as the blood levels of pemphigus antibodies, will be measured at baseline prior to entry into the trial and periodically during the trial.
The goal of the study is to determine whether there is a difference between the two treatments in the rate at which: 1) the activity and extent of the disease improves, 2) the dose of corticosteroids required to treat the disease can be reduced, and 3) the blood level of pemphigus antibodies decrease.
This trial will test this hypothesis by examining whether IVIg treatment given with cyclophosphamide results in a more rapid decline in circulating pemphigus antibodies than when given alone.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10016
- NYU Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Lesions consistent with pemphigus foliaceus or vulgaris
- Diagnosis confirmed by histology and IIF ≥ 40 within past month
- On ≥20mg/day of prednisone per day for two weeks or ≥ 80mg/day for one week
- Women of childbearing potential negative HCG obtained two weeks prior to first IVIg
- Agrees to two acceptable forms of contraception* if randomized to cyclophosphamide group:
- IUD (except progesterone T), Combination oral contraceptives, transdermal patch, vaginal ring, hormonal injectables or implantables, male latex condom, diaphragm, cervical cap, or vaginal sponge (contains spermicide)
- Normal organ function confirmed by CBC, UA, LFTs and Ig levels within defined inclusion criteria
- Responds yes to at least one of the criteria below:
- Persistence of clinical manifestations of disease despite steroid treatment
- Flare in disease activity after an attempt at steroid tapering
- Failure of established lesions to heal
- Rapidly progressive disease.
- Conventional therapy is relatively contraindicated i.e. side effects, co-morbid conditions
- systemic infections, peptic ulcers, osteoporosis, hypertension, cataracts or others
Exclusion Criteria:
- Use of IVIg within past 3 weeks or the use of a cytotoxic drug within the past 2 weeks
- Participating in another clinical trial at the time of screening and enrollment
- Medical condition that precludes use of IVIg or cyclophosphamide (i.e. pregnancy breastfeeding, underlying chronic infection, concurrent opportunistic infection, sepsis or volume depletion
- Renal insufficiency ( GFR <90, proteinuria (>1+, x 2), creatinine >1.8 or increased WBC or RBCs which cannot be explained by cystitis.)
- Known hypersensitivity to study drugs, IVIg or cyclophosphamide
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Group A
IVIg alone (intravenous immunoglobulin)
|
Gamunex 10% 500/mg/kg/day x four days per cycle total of four cycles
Other Names:
|
Experimental: Group B
IVIg with cyclophosphamide
|
Gamunex 10% 500/mg/kg/day x four days per cycle total of four cycles
Other Names:
cyclophosphamide dose of 2mg/kg/day divided into three-times daily oral administration
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Clinical Outcome: Extent and Severity of Disease
Time Frame: 6 - 10 weeks after initiation of therapy
|
6 - 10 weeks after initiation of therapy
|
Serum Levels of Pemphigus Antibodies
Time Frame: 6-10 weeks after initiation of therapy
|
6-10 weeks after initiation of therapy
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Toxicity of Treatment: Measured in Renal Toxicity, Myelosuppression or Hepatic Toxicity
Time Frame: Throughout course of study
|
Throughout course of study
|
Ability to be Weaned Off Steroids
Time Frame: Measured 6 and 10 weeks after initiation of IVIg treatment
|
Measured 6 and 10 weeks after initiation of IVIg treatment
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jean-Claude Bystryn, M.D., NYU Medical Center
Publications and helpful links
General Publications
- Green MG, Bystryn JC. Effect of intravenous immunoglobulin therapy on serum levels of IgG1 and IgG4 antidesmoglein 1 and antidesmoglein 3 antibodies in pemphigus vulgaris. Arch Dermatol. 2008 Dec;144(12):1621-4. doi: 10.1001/archdermatol.2008.503.
- Czernik A, Bystryn JC. Kinetics of response to conventional treatment in patients with pemphigus vulgaris. Arch Dermatol. 2008 May;144(5):682-3. doi: 10.1001/archderm.144.5.682. No abstract available.
- Czernik A, Beutner EH, Bystryn JC. Intravenous immunoglobulin selectively decreases circulating autoantibodies in pemphigus. J Am Acad Dermatol. 2008 May;58(5):796-801. doi: 10.1016/j.jaad.2008.01.007.
- Czernik A, Bystryn JC. Improvement of intravenous immunoglobulin therapy for bullous pemphigoid by adding immunosuppressive agents: marked improvement in depletion of circulating autoantibodies. Arch Dermatol. 2008 May;144(5):658-61. doi: 10.1001/archderm.144.5.658.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Immune System Diseases
- Autoimmune Diseases
- Skin Diseases, Vesiculobullous
- Pemphigus
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Cyclophosphamide
- Antibodies
- Immunoglobulins
- Immunoglobulins, Intravenous
- gamma-Globulins
- Rho(D) Immune Globulin
Other Study ID Numbers
- 3343
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pemphigus Vulgaris
-
Cabaletta BioRecruitingMucosal -Dominant Pemphigus VulgarisUnited States
-
Cairo UniversityCompletedOral Pemphigus VulgarisEgypt
-
Hoffmann-La RocheAspreva PharmaceuticalsCompletedPemphigus Vulgaris (PV)Turkey, Switzerland, United States, Germany, United Kingdom, Ukraine, Israel, Canada
-
argenxCompletedPemphigus Vulgaris | Pemphigus FoliaceusUnited States, Australia, Bulgaria, China, France, Georgia, Germany, Greece, Hungary, India, Israel, Italy, Japan, Poland, Romania, Russian Federation, Serbia, Spain, Turkey, Ukraine, United Kingdom
-
National Institute of Allergy and Infectious Diseases...Rho Federal Systems Division, Inc.; Autoimmunity Centers of ExcellenceTerminatedPemphigus Vulgaris | Pemphigus FoliaceusUnited States
-
argenxCompletedPemphigus Vulgaris | Pemphigus FoliaceusGermany, Hungary, Israel, Italy, Ukraine
-
argenxTerminatedPemphigus Vulgaris | Pemphigus FoliaceusUnited States, Germany, Italy, Australia, Bulgaria, China, France, Georgia, Greece, Hungary, India, Israel, Japan, Poland, Romania, Russian Federation, Serbia, Spain, Turkey, Ukraine, United Kingdom
-
Assistance Publique - Hôpitaux de ParisInstitut National de la Santé Et de la Recherche Médicale, FranceUnknownPemphigus Vulgaris | Pemphigus FoliaceusFrance
-
Alexion PharmaceuticalsTerminatedPemphigus | Pemphigus Vulgaris | Pemphigus FoliaceusUnited States
-
Principia Biopharma, a Sanofi CompanyPrincipia Biopharma Australia Pty Ltd.CompletedPemphigus VulgarisIsrael, Australia, Greece, Croatia, France
Clinical Trials on intravenous immunoglobulin
-
University Health Network, TorontoRecruiting
-
Laboratoire français de Fractionnement et de BiotechnologiesTFS Trial Form SupportCompletedMotor Neuron DiseaseSpain, United Kingdom, Italy, France
-
The University of Hong KongQueen Elizabeth Hospital, Hong Kong; Queen Mary Hospital, Hong Kong; Pamela Youde... and other collaboratorsCompleted
-
Peking Union Medical College HospitalTongji HospitalUnknown
-
Wei WangUnknownIntracranial Hemorrhage, HypertensiveChina
-
Johns Hopkins UniversityTerminatedAutoimmunity | Dysmotility SyndromeUnited States
-
University of AarhusCompletedMultifocal Motor NeuropathyDenmark
-
Universidad Politecnica de MadridRecruitingImmunoglobulin G4-Related Disease | Symptoms and Signs | Immunoglobulin E-Mediated Food Allergy | Adverse Reaction to FoodSpain
-
Assiut UniversityUnknownPleural Effusion
-
Rigshospitalet, DenmarkThe Ministry of Science, Technology and Innovation, DenmarkCompletedSecondary Recurrent MiscarriageDenmark